SREBF1 and metabolic dysfunction-associated steatotic liver disease: Interestingly, the work of Chhimwal et al. (2023) focused on targeting the mTOR/SREBP-1c axis to treat non-alcoholic fatty liver disease (NAFLD), a condition with an important inflammatory component.